Medgenics announces successful closing of $4m convertible debenture issue

Medgenics, the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, has successfully raised additional funds to finance further advances with its Phase I/II clinical trial for its product EPODURE (for the treatment of anaemia).